Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Oramed Pharmaceuticals (ORMP) Revenue (2016 - 2025)

Oramed Pharmaceuticals filings provide 8 years of Revenue readings, the most recent being $2.0 million for Q1 2025.

  • Quarterly Revenue changed N/A to $2.0 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Dec 2025, changed N/A year-over-year, with the annual reading at $2.0 million for FY2025, N/A changed from the prior year.
  • Revenue hit $2.0 million in Q1 2025 for Oramed Pharmaceuticals, up from $674000.0 in the prior quarter.
  • Across five years, Revenue topped out at $2.7 million in Q3 2021 and bottomed at $666000.0 in Q1 2022.
  • Average Revenue over 4 years is $1.1 million, with a median of $678000.0 recorded in 2022.
  • Peak annual rise in Revenue hit 0.0% in 2023, while the deepest fall reached 0.0% in 2023.
  • Oramed Pharmaceuticals' Revenue stood at $2.7 million in 2021, then tumbled by 66.56% to $904000.0 in 2022, then dropped by 25.44% to $674000.0 in 2023, then soared by 196.74% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Revenue are $2.0 million (Q1 2025), $674000.0 (Q2 2023), and $666000.0 (Q1 2023).